Company research
Rezolute, Inc.
CIK 1509261Updated Nov 13, 2026
SecurityRZLT · NASDAQ · equity
Name history
AntriaBio, Inc. · through Dec 7, 2017FITS MY STYLE INC · through Jan 11, 2013
RZLT price & chart
Loading TradingView…
NASDAQ:RZLT on TradingView ↗About the company
Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.
In the news
Rezolute to Participate in Upcoming Investor Conferences ↗
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute (RZLT) ↗
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute News provided by Faruqi & Faruqi, LLP Jan 29, 2026, 08:35 ET Share this article Share to X Share this article Share to X Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wil ↗
Recent filings
SCHEDULE 13G - filed by PRUDENTIAL FINANCIAL INC regarding Rezolute, Inc.
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
FWP - filed by Rezolute, Inc. regarding Rezolute, Inc.
424B5 filing
EFFECT filing
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 125,459,000Source | 94,739,000Source | 87,737,000Source | 138,629,000Source | 112,007,000Source | 102,150,000Source | 158,664,000Source | 123,414,000Source | 112,849,000Source | 175,490,000Source | 132,737,000Source | 123,721,000Source |
| Property, Plant and Equipment, NetUSD | 49,000Source | 80,000Source | 110,000Source | 57,000Source | 87,000Source | 119,000Source | 64,000Source | 95,000Source | 41,000Source | 72,000Source | 103,000Source | 139,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 11,236,000Source | 14,596,000Source | 5,930,000Source | 11,944,000Source | 8,932,000Source | 12,504,000Source | 9,098,000Source | 10,472,000Source | 10,615,000Source | 94,107,000Source | 70,396,000Source | 16,036,000Source |
| Assets, CurrentUSD | 122,049,000Source | 88,735,000Source | 82,210,000Source | 135,106,000Source | 98,694,000Source | 96,085,000Source | 154,708,000Source | 110,178,000Source | 110,511,000Source | 171,145,000Source | 128,653,000Source | 104,910,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,781,000Source | 1,843,000Source | 2,188,000Source | 2,168,000Source | 2,154,000Source | 3,487,000Source | 2,514,000Source | 1,905,000Source | 2,710,000Source | 3,287,000Source | 1,779,000Source | 3,014,000Source |
| Operating Lease, Right-of-Use AssetUSD | 918,000Source | 1,485,000Source | 2,006,000Source | 1,064,000Source | 1,619,000Source | 2,130,000Source | 1,208,000Source | 1,751,000Source | 769,000Source | 1,348,000Source | 1,880,000Source | 2,054,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 8,625,000Source | 12,170,000Source | 16,876,000Source | 10,631,000Source | 12,418,000Source | 10,422,000Source | 11,496,000Source | 9,973,000Source | 12,162,000Source | 13,363,000Source | 11,734,000Source | 7,549,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 96,000Source | 61,000Source | 40,000Source | 96,000Source | 61,000Source | 40,000Source | 91,000Source | 55,000Source | 96,000Source | 87,000Source | 53,000Source | 37,000Source |
| Additional Paid in CapitalUSD | 577,804,000Source | 461,931,000Source | 377,367,000Source | 572,635,000Source | 460,016,000Source | 381,154,000Source | 569,034,000Source | 457,919,000Source | 582,152,000Source | 565,903,000Source | 450,473,000Source | 377,471,000Source |
| Retained Earnings (Accumulated Deficit)USD | -460,951,000Source | -379,466,000Source | -306,468,000Source | -444,780,000Source | -360,552,000Source | -289,418,000Source | -422,006,000Source | -344,822,000Source | -481,442,000Source | -403,856,000Source | -329,444,000Source | -260,985,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -115,000Source | 43,000Source | -78,000Source | 47,000Source | 64,000Source | -48,000Source | 49,000Source | 289,000Source | -119,000Source | -7,000Source | -79,000Source | -351,000Source |
| Stockholders' Equity Attributable to ParentUSD | 116,834,000Source | 82,569,000Source | 70,861,000Source | 127,998,000Source | 99,589,000Source | 91,728,000Source | 147,168,000Source | 113,441,000Source | 100,687,000Source | 162,127,000Source | 121,003,000Source | 116,172,000Source |
| Liabilities and EquityUSD | 125,459,000Source | 94,739,000Source | 87,737,000Source | 138,629,000Source | 112,007,000Source | 102,150,000Source | 158,664,000Source | 123,414,000Source | 112,849,000Source | 175,490,000Source | 132,737,000Source | 123,721,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 7,704,000Source | 10,527,000Source | 6,957,000Source | 9,529,000Source | 10,608,000Source | 8,008,000Source | 10,209,000Source | 7,991,000Source | 11,418,000Source | 11,912,000Source | 9,606,000Source | 5,200,000Source |
| Operating Lease, Liability, CurrentUSD | 673,000Source | 615,000Source | 552,000Source | 666,000Source | 599,000Source | 538,000Source | 650,000Source | 584,000Source | 658,000Source | 632,000Source | 568,000Source | 541,000Source |
| Accounts Payable, CurrentUSD | 3,195,000Source | 6,502,000Source | 3,499,000Source | 3,783,000Source | 3,149,000Source | 3,593,000Source | 3,259,000Source | 2,176,000Source | 5,026,000Source | 5,809,000Source | 4,901,000Source | 3,269,000Source |
| Operating Lease, Liability, NoncurrentUSD | 438,000Source | 1,160,000Source | 1,819,000Source | 619,000Source | 1,333,000Source | 1,975,000Source | 804,000Source | 1,499,000Source | 276,000Source | 983,000Source | 1,660,000Source | 1,937,000Source |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -18,150,000Source | -15,378,000Source | -77,586,000Source | -74,412,000Source | -68,459,000Source | -51,787,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,531,000Source | 1,400,000Source | 14,460,000Source | 7,121,000Source | 7,360,000Source | 7,268,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -2,515,000Source | -2,194,000Source | -748,000Source | 1,421,000Source | 1,083,000Source | 2,136,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -17,430,000Source | -16,014,000Source | -64,635,000Source | -69,075,000Source | -57,368,000Source | -44,481,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -68,490,000Source | -49,410,000Source | -21,098,000Source | -14,541,000Source | 48,699,000Source | -101,464,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 153,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 3,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 911,000Source | 5,500,000Source | 2,241,000Source | 107,327,000Source | 63,029,000Source | 11,571,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -85,009,000Source | -59,924,000Source | -83,492,000Source | 23,711,000Source | 54,360,000Source | -134,374,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 11,236,000Source | 14,596,000Source | 11,944,000Source | 8,932,000Source | 9,098,000Source | 10,472,000Source | 10,615,000Source | 94,107,000Source | 70,396,000Source | 16,036,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 4,420,000Source | 1,905,000Source | 3,411,000Source | 1,445,000Source | 2,531,000Source | 1,400,000Source | 14,460,000Source | 7,121,000Source | 7,360,000Source | 7,268,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 31,000Source | 31,000Source | 36,000Source | 30,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | -6,000Source | — | 6,000Source | -15,000Source | -15,000Source | — | — | — | -5,000Source |
| General and Administrative ExpenseUSD | — | — | 5,954,000Source | 4,740,000Source | 9,873,000Source | 4,453,000Source | 6,668,000Source | 4,187,000Source | 29,168,000Source | 18,367,000Source | 14,680,000Source | 12,177,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -16,171,000Source | -18,914,000Source | -22,774,000Source | -15,730,000Source | -18,150,000Source | -15,378,000Source | -77,586,000Source | -74,412,000Source | -68,459,000Source | -51,787,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -77,586,000Source | -74,412,000Source | -68,459,000Source | -51,787,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,195,000Source | 1,109,000Source | 1,447,000Source | 1,350,000Source | 1,667,000Source | 1,563,000Source | — | 5,482,000Source | 1,964,000Source | 4,203,000Source |
| Operating ExpensesUSD | — | — | 17,366,000Source | 20,023,000Source | 24,221,000Source | 17,080,000Source | 19,817,000Source | 16,941,000Source | 82,966,000Source | 79,894,000Source | 70,423,000Source | 55,990,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 166,000Source | — | 167,000Source | — | 167,000Source | — | — | — | 607,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 946,000Source | 76,000Source | 2,276,000Source | 893,000Source | 234,000Source | — |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -17,366,000Source | -20,023,000Source | -24,221,000Source | -17,080,000Source | -19,817,000Source | -16,941,000Source | -82,966,000Source | -79,894,000Source | -70,423,000Source | -55,990,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -16,171,000Source | -18,914,000Source | -22,774,000Source | -15,730,000Source | -18,150,000Source | -15,378,000Source | -77,586,000Source | -74,412,000Source | -68,459,000Source | -51,787,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.16Source | -0.27Source | -0.22Source | -0.22Source | -0.18Source | -0.22Source | -0.75Source | -0.98Source | -1.33Source | -1.01Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.16Source | -0.27Source | -0.22Source | -0.22Source | -0.18Source | -0.22Source | -0.75Source | -0.98Source | -1.33Source | -1.01Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 104,040,292Source | 70,031,041Source | 103,687,064Source | 69,940,319Source | 103,422,647Source | 69,736,150Source | 103,907,114Source | 75,999,290Source | 51,465,000Source | 51,187,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 104,040,292Source | 70,031,041Source | 103,687,064Source | 69,940,319Source | 103,422,647Source | 69,736,150Source | 103,907,114Source | 75,999,290Source | 51,465,000Source | 51,187,000Source |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 8,000Source | 8,000Source | 31,000Source | 31,000Source | 36,000Source | 30,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | -6,000Source | — | 6,000Source | -15,000Source | -15,000Source | — | — | — | -5,000Source |
| General and Administrative ExpenseUSD | — | — | 5,954,000Source | 4,740,000Source | 9,873,000Source | 4,453,000Source | 6,668,000Source | 4,187,000Source | 29,168,000Source | 18,367,000Source | 14,680,000Source | 12,177,000Source |
| Interest and Other IncomeUSD | — | — | 1,195,000Source | 1,115,000Source | 1,447,000Source | 1,344,000Source | 1,682,000Source | 1,578,000Source | 5,380,000Source | 5,482,000Source | 4,870,000Source | 4,208,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -77,586,000Source | -74,412,000Source | -68,459,000Source | -51,787,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,195,000Source | 1,109,000Source | 1,447,000Source | 1,350,000Source | 1,667,000Source | 1,563,000Source | — | 5,482,000Source | 1,964,000Source | 4,203,000Source |
| Operating ExpensesUSD | — | — | 17,366,000Source | 20,023,000Source | 24,221,000Source | 17,080,000Source | 19,817,000Source | 16,941,000Source | 82,966,000Source | 79,894,000Source | 70,423,000Source | 55,990,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 166,000Source | — | 167,000Source | — | 167,000Source | — | — | — | 607,000Source |
| Research and Development ExpenseUSD | — | — | 11,412,000Source | 15,283,000Source | 14,348,000Source | 12,627,000Source | 13,149,000Source | 12,754,000Source | 53,798,000Source | 61,527,000Source | 55,743,000Source | 43,813,000Source |
Offerings
Registration 333-299867
Filing attachments
tm2627558d10_ex99-1.htm · 8-K · 2026-11-13
Exhibit 99.1 Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation Topline results for the completed study, along with additional study details including statistical analysis of the primary endpoint, are expected by mid-December 2026 REDWOOD CITY, Calif., November 13, 2026 - Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, m…
Read attachment ↗tm2627558d4_ex4-6.htm · S-3 · 2026-11-05
Exhibit 4.6 REZOLUTE, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of _______, 20__ Debt Securities Table of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION,…
Read attachment ↗tm2628931d2_ex99-1.htm · 8-K · 2026-11-05
Exhibit 99.1 Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update REDWOOD CITY, Calif., November 5, 2026 - Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the first quarter ended September 30, 2026. Tumor HI upLIFT, a Phase 3, single-arm, op…
Read attachment ↗tm2628517d1_ex99-1.htm · 8-K · 2026-10-29
Exhibit 99.1 A Late - stage Ultra - rare Disease Company Treating Refractory Hypoglycemia Corporate Presentation Forward Looking Statements 2 This presentation, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward - looking statements regarding our prospective performance and strategies within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act of 1934, as amended. We intend such f…
Read attachment ↗tm2627620d1_ex99-1.htm · 8-K · 2026-10-14
Exhibit 99.1 Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism Topline results expected mid-December 2026 REDWOOD CITY, Calif., October 14, 2026 - Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that the open-label Phase 3 study of ersodetug in tumor HI (upLIFT) is now fully enrolled and top…
Read attachment ↗tm2626976d1_ex99-1.htm · 8-K · 2026-10-05
Exhibit 99.1 Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities On track to report topline results for the Phase 3 upLIFT study in tumor HI this quarter REDWOOD CITY, Calif., October 5, 2026 - Rezolute, Inc. (Nasd…
Read attachment ↗